Jinyu Bio-technology Co., Ltd. (600201.SS) has a MoatMap StockRank of 42/100 based on Quality (61/100), Value (17/100), and Momentum (51/100) factor scores. The current signal is HOLD. Jinyu Bio-technology is focused on animal vaccines, which does not align with our current structural macro themes or offer an asymmetric 18-month risk-reward profile.
Jinyu Bio-technology is a leading private-sector biopharmaceutical company in China, specializing in animal vaccines and diagnostic reagents. The company operates state-of-the-art manufacturing facilities and holds the distinction of hosting the national laboratory for Foot-and-Mouth Disease vaccine research. Its focus on high-quality, market-driven veterinary products has secured its position as a preferred supplier to large-scale farming enterprises.
| Price | $1.75 |
| Market Cap | $1.9B |
| P/E (TTM) | 124.78 |
| P/E (Forward) | 46.79 |
| Price/Book | 2.25 |
| Return on Equity | 1.8% |
| Return on Invested Capital | 1.8% |
| Debt/Equity | 0.02 |
| Gross Margin | 52.1% |
| Operating Margin | 17.9% |
| Revenue Growth | -1.5% |
| Dividend Yield | 0.3% |
| Free Cash Flow | $2M |
Jinyu Bio-technology Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).